FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:260-262 January 26, 1995 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Acute myelogenous leukemia (AML) is characterized by both an increase in the number of white cells and arrest of their normal maturation and function, which causes anemia, granulocytopenia, and thrombocytopenia. The goal of treatment is to eliminate all neoplastic hematopoietic cells in the marrow, peripheral blood, and elsewhere. This goal can be accomplished in some but not all adult patients with AML through the use of two distinct, consecutive phases of treatment. The combination chemotherapy administered during the first phase in a patient with newly diagnosed AML is intended to induce a complete remission, a condition in which leukemic cells . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Cilloni, D., Messa, F., Arruga, F., Defilippi, I., Gottardi, E., Fava, M., Carturan, S., Catalano, R., Bracco, E., Messa, E., Nicoli, P., Diverio, D., Sanz, M. A., Martinelli, G., Lo-Coco, F., Saglio, G. (2008). Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. haematol 93: 921-924 [Abstract] [Full Text]  
• Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M. G., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., van der Lelie, H., Fey, M., Ferrant, A., Maertens, J., Gratwohl, A., Lowenberg, B. (2007). Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109: 3658-3666 [Abstract] [Full Text]  
• Nathan, P. C., Sung, L., Crump, M., Beyene, J. (2004). Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis. JNCI J Natl Cancer Inst 96: 38-45 [Abstract] [Full Text]  
• Harousseau, J.-L., Cahn, J.-Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.-F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P., Herve, P. (1997). Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia. Blood 90: 2978-2986 [Abstract] [Full Text]  
• (1995). TRANSPLANTATION VS. CHEMOTHERAPY IN AML. JWatch General 1995: 3-3 [Full Text]